Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
David R. Gandara
No relevant relationships to disclose
Sandrine Hiret
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Fabrice Barlesi
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Jeannick Madelaine
No relevant relationships to disclose
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Karen L. Reckamp
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI
Christine Audebert
No relevant relationships to disclose
Byoung Chul Cho
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Fadi S. Braiteh
Consultant or Advisory Role - Agendia; Spectrum Pharmaceuticals
Honoraria - Amgen; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Dendreon; Genomic Health; INSYS; Myriad Genetics; Novartis; Pfizer
Research Funding - Bayer; Foundation Medicine; Genentech; Genomic Health; GlaxoSmithKline; Lilly; Merrimack; Myriad Genetics; Novartis; Onyx; Pfizer
Robert M. Jotte
No relevant relationships to disclose
Yuehui Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Daniel J. Schramek
Employment or Leadership Position - GlaxoSmithKline
Alexandra M. Piepszak
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Olivia S. Gardner
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vijay Gopal Reddy Peddareddigari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Natasha B. Leighl
No relevant relationships to disclose